Article Information
History
- August 13, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Hamed Hosseini1,
- Anahita Sadeghi2,
- Payam Tabarsi3,
- Azin Etemadimanesh4,
- Ilad Alavi Darazam3,
- Nasser Aghdami4,
- Saeed Kalantari5,
- Mehrdad Hasibi4,
- Azar Hadadi4,
- Farhang Babamahmoodi6,
- Mansooreh Momen-Heravi7,
- Ahmad Hormati8,9,
- Yunes Panahi10,
- Rozita Khodashahi11 and
- Mohammadreza Salehi4,*
- 1Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences
- 2Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
- 3Department of Infectious Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
- 5Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran
- 6Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
- 7Department of infectious diseases, faculty of medicine, Kashan university of medical sciences, Kashan, Iran
- 8Gastroenterology and Hepatology Disease Research Center, Oom university of medical sciences, Iran
- 9Gastrointestinal and Liver Diseases Research Center, Iran university of medical sciences, Tehran, Iran
- 10Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
- 11Department of Infectious disease and tropical medicine, Faculty of Medicine, Mashhad university of medical sciences, Mashhad, Iran
- ↵*Corresponding author:
Mohammadreza Salehi M.D., Department of Infectious Disease, Tehran University of Medical Sciences. Imam Khomeini hospital complex, Gharib St., Tehran, Iran. Email: salehi.mohamad3{at}gmail.com, Cellphone: +989123159842
Posted August 13, 2021.
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
